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a b s t r a c t
Cortisol dysregulation has been proposed to be involved in depression. Hypothalamic–pituitary–adrenal
(HPA) axis dysregulation associated with major depressive disorder (MDD) was previously reported to be
higher in the elderly. Furthermore, insulin resistance and the prevalence of type 2 diabetes are known to
increase with aging. The aim of the present study was to determine whether a relationship existed
between plasma cortisol levels following the dexamethasone/corticotrophin-releasing hormone (DEX/
CRH) test and insulin resistance evaluated by the homeostasis model assessment of insulin resistance
(HOMA-R) in elderly MDD subjects. Fifteen unmedicated MDD inpatients and 17 age- and sex-matched
healthy controls participated in this study. After overnight fasting, blood samples were collected to
measure plasma glucose and insulin concentrations, estimate HOMA-R, and perform the DEX/CRH test to
evaluate HPA axis function. The value of the area under the time curve of plasma cortisol concentrations
(CortAUC) and peak cortisol values (Cortpeak) following the administration of DEX/CRH both correlated
with HOMA-R in MDD group. In contrast, neither CortAUC nor Cortpeak correlated with HOMA-R in
controls. This is the ﬁrst study to directly demonstrate the relationship between HPA axis dysregulation
assessed with the DEX/CRH test and the index of insulin resistance estimated as HOMA-R in elderly MDD
patients.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
A relationship has been identiﬁed between MDD and type
2 diabetes, which have also been proposed to partially share a
common etiology (Iwata et al., 2013); MDD was shown to increase
the incidence of type 2 diabetes (relative hazard [RH] 1.63, 95% CI
1.31–2.02) (Golden et al., 2004) and the comorbidity rate of MDD
in type 2 diabetic patients was estimated to be higher than that in
the non-diabetic population (Gavard et al., 1993). A meta-analysis
performed by Gavard et al. (1993) revealed that the prevalence of
depression in current diabetic patients ranged between 8.5% and
27.3% (mean¼14.0%), which was three-fold higher than the pre-
valence of MDD in the general adult population.
The risk factors for MDD in diabetic patients include the burden
of diabetes management and arteriosclerosis (Schillerstrom et al.,
2008). On the other hand, the risk factors for diabetes in patients
with depression involve reduced daily activities, overeating, and
hypercortisolemia (Pariante and Lightman, 2008). Hypercortisole-
mia has been attributed to hypothalamic–pituitary–adrenal (HPA)
axis dysregulation, which is one of the most reliable biological
ﬁndings of MDD (Pariante and Lightman, 2008), has been impli-
cated in the development of insulin resistance (Manoudi et al.,
2012), and is a risk factor for type 2 diabetes (Brown et al., 2004).
However, evidence for the relationship between hypercortisolemia
and insulin resistance is limited to a cross-sectional study that
only recruited normal volunteers (Rizza et al., 1982). This study
demonstrated that cortisol-induced insulin resistance was caused
by a decrease in both hepatic and extrahepatic sensitivity to
insulin.
HPA axis dysregulation associated with MDD was previously sho-
wn to be more prevalent in the elderly (Hatzinger et al., 2011), and
insulin resistance and the prevalence of type 2 diabetes have both been
reported to increase with aging (Rowe et al., 1983). Regarding depres-
sion, community-based studies identiﬁed a relationship between aging
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and prevalence of MDD (Beekman et al., 1999; Naismith et al., 2012).
Moreover, a meta-analysis revealed that aging itself may be an imp-
ortant risk factor for MDD (Snowdon, 2001). A previous study also
found that the prevalence of type 2 diabetes was the highest in the
elderly (Danaei et al., 2011). Taken together, these ﬁndings suggested
that a positive relationship exists between hypercortisolemia arising
from HPA axis dysregulation and insulin resistance in elderly MDD
patients.
Elevated cortisol levels have been shown to worsen glucose
tolerance (Di Dalmazi et al., 2012). Insulin resistance may aggravate
type 2 diabetes and cardiovascular disease, but not hypercortisole-
mia, which may develop due to the excess secretion of adrenocorti-
cotrophic hormone (ACTH) or administration of a glucocorticoid
treatment, but not directly from insulin resistance (Meigs, 2003;
Prague et al., 2013). Therefore, we hypothesized that depression or
depressive episodes may have effects on cortisol dysregulation and
also that the resultant hypercortisolemia may subsequently lead to
the development of insulin resistance in patients with depression. In
the present study, we investigated whether hypercortisolemia result-
ing from HPA axis dysregulation was directly associated with insulin
resistance in elderly MDD patients. The primary aim of the present
study was to determine whether plasma cortisol levels following the
dexamethasone/corticotrophin-releasing hormone (DEX/CRH) test
correlated with insulin resistance evaluated with HOMA-R in elderly
MDD subjects.
2. Methods
2.1. Subjects
Fifteen unmedicated inpatients from the psychiatry ward, Tottori University
Hospital, Yonago, Japan and 17 age- and sex-matched controls participated in this
study with written informed consent between November 2008 and December 2012
following a full explanation of the study. All were older than 60 years. Fifteen
inpatients met the criteria of MDD from the Diagnostic and Statistical Manual of
Mental Disorders 4th edition (DSM-IV). The diagnosis of MDD was then conﬁrmed
by Mini-International Neuropsychiatric Interview Control (M.I.N.I) (Sheehan et al.,
1998). Seventeen control subjects were recruited from the community in Tottori,
Japan via an ofﬁcial employment agency. They met neither current nor lifetime axis
I disorders of DSM-IV, which was then conﬁrmed by M.I.N.I. Exclusion criteria for
all subjects were as follows; (1) somatic disorders such as diabetes, chronic
inﬂammatory disease, autoimmune disease, endocrine disease, and neoplasm,
which directly or the treatment of which could inﬂuence insulin resistance or
plasma cortisol levels; (2) clinical evidence of other central nervous system
disorders based on a clinical history and medical examination. Mental ability was
examined using the Mini-Mental State Examination (Folstein et al., 1975) with a
cut-off point of 24; (3) a current or past history of the abuse of illegal drugs or other
substances such as benzodiazepines and alcohol; (4) past history of a head injury;
and (5) taking any psychotropic drug such as antipsychotics, antidepressants, and
mood stabilizers for the preceding two weeks prior to this study because these
drugs are known to inﬂuence the HPA axis and insulin resistance (Bergman and
Ader, 2005; Bschor et al., 2011; Kunzel et al., 2003; Mondelli et al., 2010).
This study was approved by the Ethics Committee of Tottori University Faculty
of Medicine and all subjects gave written informed consent after a full explanation
of the study.
2.2. Physical measurements and depression scale assessment
The heights (m) and weights (kg) of elderly MDD subjects were measured on
admission, and just before this study for the control subjects. The Hamilton
depression scale (HAM-D17) (Hamilton, 1960) was assessed in elderly MDD
subjects.
2.3. Assessment of HPA function
The DEX/CRH test is the most sensitive measurement of HPA axis regulation
(Kunugi et al., 2012), and was, thus, conducted to assess HPA axis regulation in all
subjects. The test was performed with a PO pretreatment of 1.5 mg DEX (‘decadron’
0.5 mg, Nichiiko Pharmaceutical Corporation, Toyama, Japan) at 23:00 h. An IV
catheter with heparinized physiological saline was inserted into a forearm vein at
14:30 h on the following day, and 100 μg human CRH (hCRH ‘TANABE’, Mitsubishi
Tanabe Pharma Corporation, Osaka, Japan) was injected through the catheter at
15:00 h immediately after the ﬁrst (¼ 0 min) blood sampling. Blood samples were
taken 30, 60, and 90 min after the injection of CRH in order to measure plasma
ACTH and cortisol concentrations. Subjects rested supine in hospital beds through-
out the test. Blood samples were cooled in ice water, rapidly centrifuged in a tube
for 10 min at 3000 rpm at 4 1C, and then stored at 20 1C until later analyses.
Plasma ACTH and cortisol concentrations were measured using an electrochemi-
luminescent immunoassay and chemiluminescent enzyme immunoassay, respec-
tively, at SRL Co. (Tokyo, Japan). The limits of detection for ACTH and cortisol were
5.0 pg/ml and 1.0 μg/dl, respectively. ACTHbase and Cortbase were deﬁned as the
plasma concentrations of ACTH and cortisol, respectively, in the blood sample
obtained at 15:00 h. ACTH30, ACTH60, and ACTH90 were deﬁned as the plasma ACTH
concentrations measured 30, 60, and 90 min, respectively, after the IV infusion of
CRH. Cort30, Cort60, and Cort90 were similarly designated for plasma cortisol
concentrations. The area under the time curve (AUC) was calculated according to
the trapezoidal rule (e.g. CortAUC for the AUC of cortisol). Cortpeak was the peak
value of the plasma cortisol concentration in response to CRH. ACTHAUC and
ACTHpeak were deﬁned in a similar manner. Regarding criteria for the suppression
of cortisol levels with DEX, we followed those described in a previous study
(Kunugi et al., 2012), in which abnormal “non-suppression” was deﬁned as Cortbase
of Z5.0 μg/dl irrespective of the size of Cortpeak, and “intermediate-suppression”
as Cortbase of o5.0 μg/dl and Cortpeak of Z5.0 μg/dl.
2.4. Assessment of insulin resistance
In the present study, insulin resistance was assessed with the homeostasis
model assessment of insulin resistance (HOMA-R) because it is one of the most
extensively used measurements of insulin resistance in clinical settings (Wallace
et al., 2004). Its formula is the basal insulin level multiplied by the basal plasma
glucose concentration divided by 22.5. Normal values were previously estimated as
1.6270.96 (Matthews et al., 1985). After overnight fasting, blood samples were
collected to determine plasma glucose and insulin concentrations. Plasma glucose
levels were measured using an enzymatic assay and plasma insulin levels were
measured using a chemiluminescent immune assay at SRL Co.
2.5. Schedule of the hormonal examination
Blood samples were collected on the ﬁrst day. The PO pretreatment with 1.5 mg
DEX was conducted on the second day at 23:00 h, and the DEX/CRH test was
conducted on the third day.
2.6. Statistical analysis
In order to make comparisons between patient and control groups, an unpaired
t-test was used to assess differences in the following items; age, BMI, and fasting
blood sugar (FBS). The Mann–Whitney test was used to assess differences in the
following items; Cortpeak, ACTHpeak, CortAUC, ACTHAUC, and HOMA-R. Fisher's exact
test was used to assess differences in the ratio of sex, non-suppression, and
intermediate-suppression between the two groups. Spearman rank correlation
coefﬁcients were determined to assess the relationships among age, BMI, HAMD,
and hormonal parameters, such as ACTH, cortisol, and HOMA-R because of the
strongly skewed distribution of these hormonal parameters. A value of po0.05 was
considered signiﬁcant. Data analyses were performed using SSPS for Windows 17.0
(SSPA Inc. Chicago).
3. Results
The demographic and clinical characteristics of the elderly MDD
patients and control subjects are shown in Table 1. No signiﬁcant
differences were observed in these characteristics or FBS, Cortpeak,
CortAUC, ACTHpeak, ACTHAUC, and HOMA-R between the two groups
(Table 2). The ratio of the number of participants assessed as
abnormal, non-, and intermediate-suppression in the DEX/CRH test
was signiﬁcantly higher in the patient group than in the control
group (Fisher's exact test; po0.05, φ coefﬁcient 0.39) (Table 3).
Metabolic characteristics, endocrinal responses, age, and HAMD
for the elderly MDD subjects, controls, and all subjects are shown in
Table 4. No correlation was observed between BMI and endocrinal
parameters in all subjects, in the control subjects, and in the elderly
MDD patients, with the exception of a correlation between BMI and
HOMA-R in all subjects (Rho¼0.48; po0.05) and in the control
subjects (Rho¼0.76; po0.05). However, this correlation was not
found in the elderly MDD patients. Regarding the relationship
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between HPA axis function and insulin resistance, indices of the HPA-
axis, Cortpeak and CortAUC did not correlate with HOMA-R in all
subjects and in the control subjects. However, CortAUC and Cortpeak
both correlated with HOMA-R in the elderly MDD patients (Rho¼
0.56; po0.05, Rho¼0.54; po0.05, respectively). The relationships
between CortAUC, Cortpeak, and HOMA-R in all subjects, the control
subjects, and the elderly MDD patients are shown in Fig. 1. In the
elderly MDD patients, the total HAMD score correlated with Cortpeak
(Rho¼0.80; po0.05) and CortAUC (Rho¼0.83; po0.05), as shown in
Fig. 2. The total HAM-D score did not correlate with HOMA-R.
Furthermore, no correlation was observed between age and either
BMI or endocrinal parameters.
4. Discussion
In the present study, correlations were observed between CortAUC
or Cortpeak obtained from the DEX/CRH test and HOMA-R, an index of
insulin resistance, in the elderly MDD patients. This is the ﬁrst study
to directly demonstrate the relationship between HPA axis dysregu-
lation, as revealed by the DEX/CRH test, and insulin resistance in
elderly MDD patients.
The correlation between cortisol dysregulation and insulin resis-
tance was only observed in the elderly MDD patients. Additionally,
the ratio of participants showing abnormal, non-, or intermediate-
suppression of the DEX/CRH test was higher in the elderly MDD
patients. Thus, although this study had a cross-sectional design
in nature and, thus, cannot concretely conclude any relationship
between elevated cortisol levels and insulin resistance, our results are
consistent with the hypothesis that depressive states affect cortisol
dysregulation, and also that hypercortisolemia leads to the develop-
ment of insulin resistance in elderly patients with depression.
A correlation was observed between BMI and HOMA-R in the
control subjects, but not in the MDD patients. A previous study
reported that obesity was associated with an increased risk of
developing insulin resistance. In obese individuals, adipose tissue
releases increased amounts of non-esteriﬁed fatty acids, glycerol,
hormones, pro-inﬂammatory cytokines, and other factors that are
involved in the development of insulin resistance. The lack of a
signiﬁcant relationship between obesity and insulin resistance in
elderly MDD patients may be explained by the relatively larger
effect of elevated cortisol levels on insulin resistance in this
population.
To examine the relationship between cortisol and HOMA-R, a
multivariate analysis was considered to be appropriate in order to
assess the contribution of BMI and age; previous studies demon-
strated that BMI was positively associated with insulin resistance
(Mihic and Modi, 2008; Tjokroprawiro, 2006), and a weak negative
association has also been reported between BMI and plasma
cortisol levels (Travison et al., 2007). On the other hand, the HPA
axis associated with MDD was reported to be more prevalent in
the elderly (Hatzinger et al., 2011), and insulin resistance and the
prevalence of type 2 diabetes have both been shown to increase
with aging (Rowe et al., 1983), as discussed above. However, no
Table 1
Demographic and clinical characteristics of the patient and control groups.
MDD Control p-value
(n¼15) (n¼17)
Age (yr), mean (SD) 71.5 (7.0) 70.2 (6.0) n.s a
Male/Female 7/8 7/10 n.s b
BMI (kg/m2), mean (SD) 20.7 (3.3) 22.1 (3.1) n.s a
HAMD 22.7 (7.8)
a Unpaired t-test.
b Fisher's exact test.
Table 2
Hormonal parameters in elderly MDD patients and control subjects.
MDD Control p-value
FBS 98.9 (20.5) 98.58 (12.65) n.sa
HOMA-R 1.26 (0.66) 1.01 (0.81) n.sb
Cortpeak 9.4 (9.8) 2.73 (2.56) n.sb
CortAUC 663.6 (705.7) 181.5 (134.0) n.sb
ACTHpeak 33.3 (38.4) 9.27 (12.1) n.sb
ACTHAUC 2156.6 (2465.0) 604.68 (699.2) n.sb
a Unpaired t-test.
b Mann–Whitney test.
Table 3
Ratios of abnormal non-suppression and intermediate suppression in the elderly MDD patients and control subjects.
MDD Control φ coefﬁcient
Non-suppressiona 7/15(46.7) 2/17(11.8) po0.05 0.39
Intermediate suppressionb 0/15(0.0) 0/17(0.0)
Non-suppression and intermediate suppression 7/15(46.7) 2/17(11.8) po0.05 0.39
φ coefﬁcient Fisher's exact test.
a Deﬁned as Cortbase ofZ5.0 μg/dl irrespective of Cortpeak.
b Deﬁned as Cortbase ofo5.0 μg/dl, Cortpeak Z5.0 μg/dl.
Table 4
Metabolic characteristics, endocrinal responses, age and HAMD for the elderly MDD
subjects,controls, and all the subjects.
MDD n¼15
BMI HOMA-R Age HAMD
HOMA-R 0.35 – 0.99 0.37
Cortpeak 0.92 0.54n 0.85 0.80n
CortAUC 0.13 0.56n 0.93 0.83n
ACTHpeak 0.08 0.30 0.86 0.68n
ACTHAUC 0.08 0.35 0.88 0.66n
Age –
HAMD 0.18 0.37 0.93 –
Controls n¼17
HOMA-R 0.76n – 0.93
Cortpeak 0.18 0.06 0.52
CortAUC 0.89 0.11 0.43
ACTHpeak 0.25 0.19 0.51
ACTHAUC 0.12 0.19 0.40
Age -
MDDþcontrols n¼32
HOMA-R 0.48n – 0.60
Cortpeak 0.07 0.23 0.47
CortAUC 0.12 0.23 0.38
ACTHpeak 0.16 0.07 0.99
ACTHAUC 0.17 0.09 0.84
Age –
Spearman's Rho.
n Po0.05.
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correlation was observed between BMI and plasma cortisol levels
or HOMA-R nor between age and plasma cortisol levels or HOMA-
R, in the elderly MDD patients in the present study; therefore, we
adopted a univariate analysis.
Our results also indicated that the severity of the psychiatric
condition positively correlated with plasma cortisol levels. Recent
studies demonstrated that patients with more severe depression
had higher cortisol levels (Kunugi et al., 2006; Owashi et al., 2008),
and our results were consistent with these ﬁndings. On the other
hand, we did not ﬁnd any correlation between the severity of the
psychiatric condition and the index of insulin resistance assessed
with HOMA-R. Therefore, we hypothesized that a depressive state
may affect cortisol dysregulation, and that hypercortisolemia may
then worsen insulin resistance in elderly patients with depression.
In the present study, no signiﬁcant differences were observed in
any hormonal parameter such as Cortpeak and CortAUC between
control subjects and the elderly MDD patients (Table 2). Although
previous studies reported signiﬁcant differences in these parameters
between these groups (Kunugi et al., 2004), others disproved such
differences in HPA regulation between healthy controls and dep-
ressed subjects (Carpenter et al., 2009; Gervasoni et al., 2004). HPA
axis dysregulation was not detected in patients with the following
attributes: being outpatients, chronic patients, long-term sick leave
patients, and atypical depression patients (Kunugi et al., 2012), who
were not investigated in our study. Since the ratio of abnormal, non-,
and intermediate-suppression was signiﬁcantly higher in the patient
group, the weak statistical power due to the small number of
subjects may be the reason for the apparent lack of signiﬁcant diff-
erences in hormonal parameters between the two groups.
The number of adults over 60 years old is increasing in many
developed countries (Christensen et al., 2009). Although previous
studies demonstrated that depression indirectly inﬂuenced the
physical health of the elderly through cognitive impairments and
social factors such as a lower income and poor social support
(Mezuk et al., 2012; Takeshita et al., 2002), depression, per se, may
directly affect the physical health of the elderly through insulin
resistance and type 2 diabetes. From a clinical perspective, clinicians
should consider the risk of type 2 diabetes when they treat elderly
MDD patients.
The limitations of the present study are as follows: (1) the small
sample size; the number of participants in this study was rela-
tively small. The responses of the HPA axis, such as cortisol
responses, were highly variable (Cortpeak; mean 5.8, S.D. 7.6,
CortAUC; mean 407.5, S.D. 542, for all subjects); thus, a large
sample size is more desirable. (2) The cross-sectional design; a
longitudinal study is required to establish a relationship between
depression, HPA dysregulation, and insulin resistance. (3) The
limited characteristics of the subjects; only inpatients and the
Fig. 1. Shows the correlation between Cortpeak and CortAUC and the DEX/CRH and HOMA-R of all the subjects, the control subjects, and the elderly MDD subjects. CortAUC and
Cortpeak both correlated with HOMA-R only in the elderly MDD subjects (Rho¼0.56; po0.05, Rho¼0.54; po0.05, respectively).
Fig. 2. HAMD correlated with Cortpeak (Rho¼0.80; po0.05) and CortAUC (Rho¼0.83; po0.05) in the elderly MDD subjects.
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elderly were included in this study. Outpatients, remitted patients,
and other generations of subjects are needed to more accurately
examine the relationship between HPA dysregulation, insulin
resistance, and age; however, it is possible that the correlation
observed between cortisol levels and insulin resistance may be
speciﬁc to elderly patients. (4) Other limitations include the lack of
consideration of the duration of the current depressive episode,
frequency of depressive episodes in the life of the patient, the
nature of the depressive state, such as psychotic or non-psychotic,
typical or atypical, and a family history of diabetes. (5) The multi-
plicity of the statistical tests was not considered, and, thus, in
combination with the small sample size, the results of the present
study should be taken as exploratory at best.
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